---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-001841"
form_type: "8-K"
ticker: "ALDX"
cik: "0001341235"
company_name: "Aldeyra Therapeutics, Inc."
filed_at: "2023-12-19T23:59:59+00:00"
generated_at: "2026-06-07T10:25:57.292976+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aldeyra announces positive Phase 2 data for ADX-629 in atopic dermatitis; advancing ADX-246

## Summary
- Phase 2 trial of ADX-629 in 8 mild-to-moderate atopic dermatitis patients showed statistically significant improvement from baseline in EASI (p=0.0006) and IGA (p<0.0001).
- Three patients (38%) achieved EASI-75; one patient (13%) had complete clearance of affected body surface area; two patients (25%) reported elimination of itching.
- Only two mild treatment-related adverse events reported; no serious adverse events or discontinuations. All eight patients completed the trial.
- Company plans to initiate a randomized placebo-controlled Phase 1/2 trial of ADX-246 in H1 2024, with topline results expected in H2 2024.

## SEC filing metadata
- accession: 0001157523-23-001841
- form_type: 8-K
- ticker: ALDX
- cik: 0001341235
- company_name: Aldeyra Therapeutics, Inc.
- filed_at: 2023-12-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1341235/000115752323001841/0001157523-23-001841-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1341235/000115752323001841/a53872843.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-001841
- JSON: https://secwatch.observer/filing/0001157523-23-001841.json
- Plain text: https://secwatch.observer/filing/0001157523-23-001841.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.